Trial Profile

An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008/SAR444671) on Safety and Disease Activity in Participants With IgG4-Related Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilzabrutinib (Primary) ; Prednisone
Indications Immunoglobulin G4-related disease; Immunological disorders
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Principia Biopharma

Most Recent Events

12 Jun 2025 According to a Sanofi media release, The results were presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain, from June 11 to 14, 2025.
12 Jun 2025 Results presented in the Sanofi media release.
03 Apr 2025 According to a Sanofi media release, more detailed results will be shared at a forthcoming medical meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com